Barclays PLC Acquires 12,152 Shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR)

Barclays PLC increased its holdings in shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR) by 51.8% during the third quarter, HoldingsChannel reports. The firm owned 35,602 shares of the company’s stock after buying an additional 12,152 shares during the period. Barclays PLC’s holdings in Nature’s Sunshine Products were worth $485,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of NATR. Jacobs Levy Equity Management Inc. raised its position in Nature’s Sunshine Products by 7.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 67,258 shares of the company’s stock worth $916,000 after buying an additional 4,820 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of Nature’s Sunshine Products by 23.2% during the third quarter. Wasatch Advisors LP now owns 696,184 shares of the company’s stock valued at $9,482,000 after purchasing an additional 131,174 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its position in Nature’s Sunshine Products by 26.8% during the second quarter. Paradigm Capital Management Inc. NY now owns 695,079 shares of the company’s stock valued at $10,475,000 after purchasing an additional 146,879 shares during the period. XTX Topco Ltd purchased a new stake in Nature’s Sunshine Products in the second quarter worth approximately $180,000. Finally, Renaissance Technologies LLC grew its position in Nature’s Sunshine Products by 1.9% in the 2nd quarter. Renaissance Technologies LLC now owns 559,797 shares of the company’s stock worth $8,436,000 after purchasing an additional 10,700 shares during the period. 79.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. StockNews.com upgraded Nature’s Sunshine Products from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Canaccord Genuity Group initiated coverage on Nature’s Sunshine Products in a research note on Friday, September 13th. They set a “buy” rating and a $18.00 price target for the company. Finally, Canaccord Genuity Group started coverage on shares of Nature’s Sunshine Products in a research note on Friday, September 13th. They issued a “buy” rating and a $18.00 price objective on the stock.

Insiders Place Their Bets

In other news, major shareholder Fosun Pharmaceutical Shanghai sold 3,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $13.39, for a total value of $40,170.00. Following the transaction, the insider now directly owns 69,347 shares in the company, valued at $928,556.33. The trade was a 4.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 6,100 shares of company stock worth $80,860. Company insiders own 4.70% of the company’s stock.

Nature’s Sunshine Products Stock Performance

NASDAQ:NATR opened at $14.56 on Friday. The stock has a 50-day simple moving average of $15.23 and a two-hundred day simple moving average of $14.54. Nature’s Sunshine Products, Inc. has a 52-week low of $10.81 and a 52-week high of $21.72. The firm has a market capitalization of $269.01 million, a PE ratio of 16.55 and a beta of 0.93.

Nature’s Sunshine Products Profile

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.